FindTrial
Sign In

VX15/2503

DRUG5 trials

Sponsors

Vaccinex Inc., Emory University

Conditions

Huntington's DiseaseMultiple SclerosisPathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Solid TumorsSquamous Cell Carcinoma of the Head and Neck

Phase 1

Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
CompletedNCT01313065
Vaccinex Inc.Solid Tumors
Start: 2011-01-31End: 2014-06-30Updated: 2014-08-13
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
CompletedNCT01764737
Vaccinex Inc.Multiple Sclerosis
Start: 2012-12-31End: 2014-11-30Updated: 2015-02-06
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Active, not recruitingNCT03690986
Emory UniversitySquamous Cell Carcinoma of the Head and Neck
Start: 2018-11-01End: 2027-11-30Updated: 2026-07-16
VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
Active, not recruitingNCT03769155
Emory UniversityPathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Start: 2018-12-13End: 2032-12-15Updated: 2026-05-05

Phase 2

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
CompletedNCT02481674
Vaccinex Inc.Huntington's Disease
Start: 2015-07-31End: 2020-08-31Updated: 2022-05-02

Related Papers

Abstract LB-C007: Enhancing immune interactions in tumor with pepinemab SEMA4D blocking antibody
Cancer Immunology Research2026-03-05
Targeting SEMA4D/PLXN signaling through reactive glia as a common pathology for the treatment of neurodegenerative disorders
Alzheimer s & Dementia2025-12-01
Neoadjuvant biomarker trial of pepinemab to enhance nivolumab or ipilimumab activity in resectable head and neck cancer.
Journal of Clinical Oncology2025-05-28
Abstract 6007: Neoadjuvant pepinemab enhances DC function associated with mature tertiary lymphoid structures and activity of immune checkpoint blockade in patients with metastatic melanoma
Cancer Research2025-04-21
Abstract 3975: Regulating dendritic cells to promote mature tertiary lymphoid structures and enhance anti-tumor immunity
Cancer Research2025-04-21
629 Neoadjuvant SEMA4D inhibitor pepinemab combination with nivolumab increases crosstalk between B cell and CD26<sup>hi</sup> T cell in patients with resectable stage III melanoma
Regular and Young Investigator Award Abstracts2023-10-311 citations
SEMA4D blocking antibody, pepinemab, is a novel potential treatment for neurodegenerative disease: Clinical proof of concept in Phase 2 HD study supports ongoing clinical development in Phase 1/2 AD study
Alzheimer s & Dementia2023-06-013 citations
613 Neoadjuvant SEMA4D blockade with nivolumab alters suppressive myeloid cells while elevating B cell and CD26<sup>hi</sup> T cell infiltration in the tumors of patients with resectable stage III melanoma
Regular and Young Investigator Award Abstracts2022-11-011 citations
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
2022-08-0843 citations
Abstract A15: Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors
Clinical Cancer Research2020-06-15
Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.
Journal of Clinical Oncology2020-05-202 citations
Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
Cancer Research2019-07-012 citations
Abstract 1545: Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies
Cancer Research2019-07-01
Abstract 1545: Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies
Immunology2019-07-01
Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
Clinical Trials2019-07-01
Pilot integrated biomarker study of VX15/2503 in combination with ipilimumab and/or nivolumab in patients with resectable metastatic melanoma.
Journal of Clinical Oncology2019-05-201 citations
Abstract PR10: Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy
Cancer Immunology Research2019-02-01
Huntington’s Disease Clinical Trials Corner: August 2018
Journal of Huntington s Disease2018-06-0131 citations
Huntington’s Disease Clinical Trials Corner: February 2018
2018-01-0144 citations
Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial.
2017-06-1651 citations

1 more papers not shown